Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PANCRELIPASE EQUIVALENT TO LIPASE & AMYLASE & PROTEASE

Form:

9 of 9 products shown

All products: Limited Use (codes 124, 125, 126, 225)

Other products in the same Health Canada class (A09AA) — coverage varies; not interchangeable

  • Amylase + lipase + protease (Creon Minimicrospheres 35): limited Use 124, 125, 126, 225

Viokace · DIN 02241933 · 16mg · tablet

Limited Use — Reason for Use code 124, 125, 126 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126 required
Write on scriptLU code 124, 125, 126 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Viokace · DIN 02241933 Manufacturer: Nestle Enterprises S.A.; listing date 2001-03-07 Health Canada: Marketed since 2020-07-02 · brand VIOKACE · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Tablet · route Oral · ingredients AMYLASE 113400 UNIT, LIPASE 20880 UNIT, PROTEASE 112500 UNIT · company Nestle enterprises s.a. · schedule Prescription
Check this DIN again · Health Canada product record

Viokace: Formulary list price $0.6521/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6521 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65603 · Verify on the e-Formulary ↗ (DIN 02241933)

Source record
DIN 02241933: Viokace Raw flags: sec12=Y, sec3=Y Item: 561600034; group id 661; item number 1649; lccId 00098; manufacturer id NSA Source form: Tab; strength: 16mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6521; ministry $0.6521 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241933 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65603
Shortage status: resolved shortage (ended 2023-08-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241933
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pancrease MT4 · DIN 00789445 · 4000 & 12000 & 12000 USP Units · Ent Microsph capsule

Limited Use — Reason for Use code 124, 125, 126 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126 required
Write on scriptLU code 124, 125, 126 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Pancrease MT4 · DIN 00789445 Manufacturer: Vivus Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-08-01 · brand PANCREASE MT 4 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients PROTEASE 10000 UNIT, LIPASE 4200 UNIT, AMYLASE 17500 UNIT · company Vivus llc. · schedule Prescription
Check this DIN again · Health Canada product record

Pancrease MT4: Formulary list price $0.7274/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7274 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9514 · Verify on the e-Formulary ↗ (DIN 00789445)

Source record
DIN 00789445: Pancrease MT4 Raw flags: sec12=Y, sec3=Y Item: 561600026; group id 659; item number 1644; lccId 00098; manufacturer id VIU Source form: Ent Microsph Cap; strength: 4000 & 12000 & 12000 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7274; ministry $0.7274 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00789445 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9514
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00789445
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Creon Minimicrospheres Micro · DIN 02445158 · 5100 & 500 & 320 Units/100mg · Gran - 100mg/Scoop

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon Minimicrospheres Micro · DIN 02445158 Manufacturer: BGP Pharma ULC; listing date 2017-04-27 Health Canada: Marketed since 2015-11-18 · brand CREON MINIMICROSPHERES MICRO · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Granules for suspension (delayed-release · route Oral · ingredients AMYLASE 5100 UNIT/100MG, LIPASE 5000 UNIT/100MG, PROTEASE 320 UNIT/100MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Creon Minimicrospheres Micro: Formulary list price $0.1912/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1912 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93037 · Verify on the e-Formulary ↗ (DIN 02445158)

Source record
DIN 02445158: Creon Minimicrospheres Micro Raw flags: sec12=Y, sec3=Y Item: 561600056; group id 660; item number 1647; lccId 00097; manufacturer id BGP Source form: Gran - 100mg/Scoop; strength: 5100 & 500 & 320 Units/100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1912; ministry $0.1912 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93037
Shortage status: resolved shortage (ended 2026-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02445158
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cotazym ECS 8 · DIN 00502790 · 8000 & 30000 & 30000 USP Units · Ent Microsph capsule

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym ECS 8 · DIN 00502790 Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01 Health Canada: Marketed since 2021-11-01 · brand COTAZYM ECS 8 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 10800 UNIT, PROTEASE 45000 UNIT, AMYLASE 42000 UNIT · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Cotazym ECS 8: Formulary list price $0.5365/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5365 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3891 · Verify on the e-Formulary ↗ (DIN 00502790)

Source record
DIN 00502790: Cotazym ECS 8 Raw flags: sec12=Y, sec3=Y Item: 561600023; group id 658; item number 1642; lccId 00097; manufacturer id ORG Source form: Ent Microsph Cap; strength: 8000 & 30000 & 30000 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.5365; ministry $0.5365 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00502790 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3891
Shortage status: anticipated shortage (last updated 2026-06-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00502790
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cotazym · DIN 00263818 · 10000 & 40000 & 35000 USP Units · capsule

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym · DIN 00263818 Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01 Health Canada: Marketed since 2022-01-07 · brand COTAZYM · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (immediate-release) · route Oral · ingredients PROTEASE 35000 UNIT, LIPASE 10000 UNIT, AMYLASE 40000 UNIT · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Cotazym: Formulary list price $0.2972/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2972 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1649 · Verify on the e-Formulary ↗ (DIN 00263818)

Source record
DIN 00263818: Cotazym Raw flags: sec12=Y, sec3=Y Item: 561600022; group id 658; item number 1641; lccId 00097; manufacturer id ORG Source form: Cap; strength: 10000 & 40000 & 35000 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2972; ministry $0.2972 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00263818 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1649
Shortage status: resolved shortage (ended 2025-04-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00263818
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Creon 10 · DIN 02200104 · 10000 & 33200 & 37500 USP Units · Ent Minimicrosph capsule

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon 10 · DIN 02200104 Manufacturer: Solvay Pharma Inc.; listing date 1998-12-31 Health Canada: Marketed since 2015-11-20 · brand CREON MINIMICROSPHERES 10 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 10000 UNIT, AMYLASE 11200 UNIT, PROTEASE 730 UNIT · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Creon 10: Formulary list price $0.2954/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2954 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36179 · Verify on the e-Formulary ↗ (DIN 02200104)

Source record
DIN 02200104: Creon 10 Raw flags: sec12=Y, sec3=Y Item: 561600030; group id 660; item number 1645; lccId 00097; manufacturer id SPH Source form: Ent Minimicrosph Cap; strength: 10000 & 33200 & 37500 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2954; ministry $0.2954 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02200104 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=36179
Shortage status: resolved shortage (ended 2024-12-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02200104
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Viokace · DIN 02230019 · 10440 & 56400 & 57100 USP Units · tablet

Limited Use — Reason for Use code 124, 125, 126 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126 required
Write on scriptLU code 124, 125, 126 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Viokace · DIN 02230019 Manufacturer: Nestle Enterprises S.A.; listing date 1997-03-14 Health Canada: Marketed since 2020-07-02 · brand VIOKACE · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Tablet · route Oral · ingredients PROTEASE 57100 UNIT, AMYLASE 56400 UNIT, LIPASE 10440 UNIT · company Nestle enterprises s.a. · schedule Prescription
Check this DIN again · Health Canada product record

Viokace: Formulary list price $0.4249/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4249 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48551 · Verify on the e-Formulary ↗ (DIN 02230019)

Source record
DIN 02230019: Viokace Raw flags: sec12=Y, sec3=Y Item: 561600029; group id 661; item number 1648; lccId 00098; manufacturer id NSA Source form: Tab; strength: 10440 & 56400 & 57100 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4249; ministry $0.4249 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230019 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48551
Shortage status: resolved shortage (ended 2022-10-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230019
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cotazym ECS 20 · DIN 00821373 · 20000 & 55000 & 55000 USP Units · Ent Microsph capsule

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cotazym ECS 20 · DIN 00821373 Manufacturer: Organon Canada Ltd./Ltee; listing date 1997-04-10 Health Canada: Marketed since 2021-12-17 · brand COTAZYM ECS 20 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 25000 UNIT, AMYLASE 100000 UNIT, PROTEASE 100000 UNIT · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Cotazym ECS 20: Formulary list price $1.4067/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.4067 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9892 · Verify on the e-Formulary ↗ (DIN 00821373)

Source record
DIN 00821373: Cotazym ECS 20 Raw flags: sec12=Y, sec3=Y Item: 561600014; group id 658; item number 1643; lccId 00097; manufacturer id ORG Source form: Ent Microsph Cap; strength: 20000 & 55000 & 55000 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.4067; ministry $1.4067 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00821373 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9892
Shortage status: anticipated shortage (last updated 2026-06-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00821373
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Creon 25 · DIN 01985205 · 25000 & 74000 & 62500 USP Units · Ent Minimicrosph capsule

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon 25 · DIN 01985205 Manufacturer: Solvay Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2015-11-20 · brand CREON MINIMICROSPHERES 25 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients AMYLASE 25500 UNIT, PROTEASE 1600 UNIT, LIPASE 25000 UNIT · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Creon 25: Formulary list price $0.9229/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9229 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13302 · Verify on the e-Formulary ↗ (DIN 01985205)

Source record
DIN 01985205: Creon 25 Raw flags: sec12=Y, sec3=Y Item: 561600025; group id 660; item number 1646; lccId 00097; manufacturer id SPH Source form: Ent Minimicrosph Cap; strength: 25000 & 74000 & 62500 USP Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.9229; ministry $0.9229 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01985205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13302
Shortage status: resolved shortage (ended 2025-07-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01985205
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:16 Digestants) and how they are covered

Matched class: 56:16 Digestants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 56:16 Digestants

LIPASE & AMYLASE & PROTEASE

· 1 products · Limited Use, codes 124, 125, 126, 225 · strengths: 35000 & 35700 & 2240 Units · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:16
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE COTAZYM® (pancreatic enzymes) is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy. Geriatrics (> 65 years of age): Clinical studies of COTAZYM® in geriatric patients have not been conducted. Pediatrics (<18 years of age): Post approval, several clinical studies have been conducted supporting the safe and effective use of COTAZYM® in pediatric patients with established pancreatic insufficiency. https://pdf.hres.ca/dpd_pm/00060547.PDF PM date: March 30, 2021 Source product: COTAZYM; DIN 00263818; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.